Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008817 | 0.86 | BRD4 (0.64) | BRD4ELANE | |
| SCHEMBL16008532 | 0.82 | BRD4 (1.00) | BRD4ELANE | |
| SCHEMBL16008102 | 0.82 | BRD4 (0.59) | BRD4 | |
| SCHEMBL16008919 | 0.82 | BRD4 (0.59) | BRD4ELANE | |
| SCHEMBL16007949 | 0.75 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16007488 | 0.74 | BRD4 (1.00) | BRD4 | |
| Ethoxycarbonyl Group SCHEMBL28043334 | 0.74 | BRD4 (0.81) | BRD4 | |
| SCHEMBL16008404 | 0.73 | BRD4 (0.65) | BRD4 | |
| SCHEMBL16007994 | 0.72 | BRD4 (0.57) | BRD4ELANE | |
| SCHEMBL16007770 | 0.72 | BRD4 (0.64) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970262-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| CN-105164127-A | Bromodomain inhibitors | ABBVIE INC | 2015-12-16 | — | — | CN | claimed |
| WO-2014164771-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | claimed |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | claimed |
| EP-2970262-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105164127-A | Bromodomain inhibitors | ABBVIE INC | 2015-12-16 | — | — | CN | disclosed |
| US-9050346-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014164771-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885ELANE 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.